Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21410716 | 0.95 | FTO (0.42) | L3MBTL1ATMFTOTACR3POLB | |
| SCHEMBL22886730 | 0.91 | L3MBTL1 (0.41) | L3MBTL1ATMFTOPPARGPPARA | |
| SCHEMBL22886544 | 0.86 | L3MBTL1 (0.44) | L3MBTL1CTSAFTOPOLBMAPT | |
| SCHEMBL22886426 | 0.84 | FTO (0.42) | L3MBTL1FTOPOLBMAPTTDP1 | |
| SCHEMBL22886773 | 0.83 | CAPN1 (0.51) | TACR3POLBMAPTTDP1CAPN1 | |
| SCHEMBL22886761 | 0.83 | RAB9A (0.40) | L3MBTL1CTSAFTOTACR3POLB | |
| SCHEMBL22886566 | 0.83 | CAPN1 (0.43) | CTSBCTSSCAPN1 | |
| SCHEMBL20028431 | 0.82 | CAPN1 (0.53) | CTSBCTSSCAPN1 | |
| SCHEMBL21854063 | 0.82 | CAPN1 (0.53) | CTSBCTSSCAPN1 | |
| SCHEMBL22886851 | 0.81 | CAPN1 (0.38) | FTOTACR3POLBMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | L3MBTL1 3275/4885ATM 3926/4885CTSA 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.